Korsana Biosciences, Inc. (KRSA)

Korsana Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Operating Activities

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024
Net Income	-49.08	-35.64	-0.53
Stock-Based Compensation	2.25	1.61	0.32
Change in Accounts Payable	-0.26	0.11	0.41
Change in Other Net Operating Assets	5.25	11.52	0.06
Operating Cash Flow	-41.84	-22.41	0.26
Operating Cash Flow Growth	-	-	-

Financing Activities

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024
Issuance of Common Stock	0.86	0.86	0.6
Financing Cash Flow	166.2	166.43	60.38

Net Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024
Net Cash Flow	124.19	144.03	60.65

Free Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024
Levered Free Cash Flow	-	-9.75	-
Unlevered Free Cash Flow	-	-9.75	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024
Change in Working Capital	4.99	11.63	0.47

Data Source: S&P Global Market Intelligence Last updated: Jun 9, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 1, 2026

Data Sources Report a data error